Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
80 Cards in this Set
- Front
- Back
What kind of drug is diazoxide?
|
Hyperglycemic
|
|
What is the mechanism of action of diazoxide?
|
Inhibit insulin release
|
|
What drug has the opposite effect of sulfonylurea?
|
Diazoxide
|
|
What drug is an oral agent for hypoglycemia of various causes including insulinoma?
|
Diazoxide
|
|
What kind of drug is glucagon?
|
Hyperglycemic
|
|
What is the mechanism of action of glucagon?
|
Binds GPCR in liver - stimulates gluconeogenesis
|
|
What hormone/drug has opposite effects of insulin?
|
Glucagon
|
|
What drug/hormone is indicated for rescue from hypoglycemic crisis?
|
Glucagon
|
|
What cells of the pancreas secrete glucagon?
|
Alpha cells of pancreatic islets
|
|
Name an oral hypoglycemic, category: incretin mimetic:
|
Exenatide
|
|
What kind of drug is exenatide?
|
Incretin mimetic
|
|
What drug is an agonist of glucagon-like-peptide-1 (GLP1)? found in the gut?
|
Exenatide
|
|
Where does exenatide act?
|
In the gut
|
|
When intracellular Ca concentration is increased, does this increase/decrease insulin secretion?
|
Increase insulin secretion
|
|
Does exenatide reduce appetite
|
Yes
|
|
What is the main worry when exenatide is given with sulfonylurea?
|
Hypoglycemia
|
|
Name 2 thiazolidinediones:
|
Rosiglitazone
Pioglitazone |
|
What thiazolidinedione has a plasma half-life of 3-4 hours?
|
Rosiglitazone
|
|
What thiazolidinedione is extensively (99.8%) bound to albumin?
|
Rosiglitazone
|
|
Thiazolidinediones should/should not be given to patient who experienced jaundice with Troglitazone?
|
Should not. Avoid in patients with compromised liver function
|
|
Pioglitazone should/should not be iven to patient who experienced jaundice on Troglitazone?
|
Should not.
|
|
What is the mechanism of thiazolidinediones (Rosiglitazone and Pioglitazone)
|
Increase target tissue insulin sensitivity
|
|
What drug class is the mechanism of action to increase target tissue insulin sensitivity?
|
Thiazolidinediones
|
|
If a patient cannot tolerate metformin, what drug class can be given instead?
|
Thiazolidinediones
|
|
Name an alpha-glucosidase inhibitor:
|
Acarbose
|
|
Acarbose is what kind of drug
|
alpha-glucosidasae inhibitor
|
|
What drug prolongs the digestion of carbs and reduces peak plasma glucose levels?
|
Acarbose
|
|
Which oral hypoglycemic has reduced risk of postprandial hyperglycemia?
|
alpha-glucosidase inhibitor Acarbose
|
|
For what drug is ADR flatulence?
|
Acarbose
|
|
What oral hypoglycemic is contraindicated in patients with colonic ulcers and IBD?
|
Acarbose
|
|
Repaglinide is what kind of oral hypoglycemic?
|
Meglitinide
|
|
Nateglinide is what kind of oral hypoglycemic?
|
Meglitinide
|
|
What is the mechanism of action of metiglinides (Repaglinide and Nateglinide)
|
Insulin secretagogue
|
|
Where do metiglinides bind to?
|
ATP-dependent K channel in beta cells
Promote closure of K channels and stimulate insulin release |
|
Name the oral hypoglycemic agent of choice to treat DMII?
|
Metformin
|
|
Metformin is what kind of oral hypoglycemic?
|
Biguanine
|
|
What drug inhibits hepatic and renal gluconeogenesis?
|
Metformin
|
|
Metformin also stimulates glucose uptake and glycolysis in peripheral tissues T/F?
|
True
|
|
Does metformin increase insulin sensitivity?
|
Yes it does
|
|
Does metformin cause hypoglycemia?
|
No it does not cause hypoglycemia
|
|
What is the main adverse reaction with sulfonylurea?
|
Hypoglycemia
|
|
Can sulfonylureas cause weight gain?
|
Yes it can
|
|
What is the most appropriate oral hypoglycemic for non-obese DMII patients?
|
Sulfonylureas
|
|
Chlorpropramide is what kind of oral hypoglycemic?
|
Sulfonylurea
|
|
Glipizide is what kind of oral hypoglycemic?
|
Sulfonylurea
|
|
Name a 1st generation sulfonylurea:
|
Chlorpropramide
|
|
Name a 2nd generation sulfonylurea:
|
Glipizide
|
|
What is the mechanism of action of sulfonylurea?
|
Insuline secretagogue
Bind to ATP dependent K channel in beta cells Promotes closure of K channel |
|
1st or 2nd generation sulfonylureas are more potent?
|
2nd generation (Glipizide)
|
|
What kind of therapy is used to treat DMII (Mono or Combination therapy?)
|
Combination therapy
|
|
What lifestyle changes are recommended for treatment of DMII?
|
Dietary and weight control
|
|
What is the most serious side effect of insulin?
|
Hypoglycemia
|
|
Impaired neurological function is a clinical manifestation of what condition?
|
Hypoglycemia
|
|
Glucose tablet, candy, glucose IM, glucagon IM are all remedies for what condition?
|
Hypoglycemia
|
|
What can accumulate at site of injections?
|
Fat accumulation
|
|
Insulin sensitizers can be combined with what (name 2) for combination therapy?
|
+ insulin
+ insuline secretagogue |
|
What two sensitizers have different mechanisms but are combined for therapy?
|
TZD and metformin
|
|
Name an ultra rapid acting insulin?
|
Lispro
|
|
When should Lispro be taken?
|
15 minutes before a meal
|
|
Name a short acting insulin preparation:
|
Regular insulin
|
|
What is the onset of regular insulin?
|
30-60 min
|
|
What insulin contains zinc insulin crystals?
|
Regular insulin
|
|
Name 2 intermediate acting insulin:
|
NPH
Lente |
|
NPH can only be administered how?
|
Subcutaneously
|
|
What insulin contains protamine zinc?
|
NPH
|
|
What insulin contains acetate buffer?
|
Lente
|
|
What insulin (2) are long acting?
|
Ultralente
Glargine |
|
Intermediate acting insulin is preferably combined with what two other types?
|
Combine with rapid and regular insulin
|
|
What insulin preparation has peakless basal insulin level?
|
Glargine
|
|
What insulin is preferred for bedtime?
|
Glargine
|
|
Endogenous insulin associates as what?
|
Hexamers
|
|
Are DMI patients responsive to oral hypoglycemics?
|
No
|
|
What is the rate limiting step for capillary absorption of insulin?
|
Subcutaneous dissociation into dimers and then into monomers
|
|
Alterations in rate of insulin hexamer dissociation result in differences in what two parameters?
|
Peak
Duration of action |
|
Insulin enters the cell through what receptor?
|
Glut2
|
|
Depolarizing or nondepolarizing cell opens VG Ca channel?
|
Depolarizing cell
|
|
What is the type of insulin receptor?
|
Tyrosine kinase
|
|
Insulin signaling occurs through what pathway?
|
MAP kinase signaling pathway
|
|
Increased ATP leads to closure of ATP dependent K channel results in what
|
Depolarization of VG Ca channels
|
|
What stimulates fusion of insulin containing vesicles to plasma membrane and subsequent exocytosis?
|
Increase in intracellular Ca
|